IDEAYA Biosciences, Inc.
$3.29B- Market cap
- $3.85B
- Debt
- +$84.13M
- Cash
- −$639.39M
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: IDYA stock price at premium vs RYN $39.86 current versus $28.79 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RYN's multiple
Implied fair value · at IDYA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · RYN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
Capital structure 85% equity / 15% debt · EV / Revenue 13.12x · EV / EBITDA 13.38x
RYN carries the larger enterprise value at $6.36B against $3.29B; RYN trades on the lower EV / Revenue multiple (13.12x vs 15.05x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
RAYONIER INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
0.47x
Net debt / EBITDA
Leverage against operating earnings
4.97x
0.43x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$842.94M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
WEYERHAEUSER CO
IDYA vs WY
SBA COMMUNICATIONS CORP
IDYA vs SBAC
AMERICAN TOWER CORP /MA/
IDYA vs AMT
IRON MOUNTAIN INC
IDYA vs IRM
$84.13M
$1.05B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.